ACTU (actuatetherapeutics.com) EV/Sales Multiple

Public company logo of Actuate Therapeutics Inc. (ACTU)

Actuate Therapeutics, Inc. (ACTU) is rapidly building its authority in oncology by developing effective inhibitors to combat severe pathologies. The enterprise value assessment via EV/Sales visualizes market expectations, where 0.00 determines the current level of this parameter. The company is focused on monetizing GSK-3 therapy for tumor suppression, although business success relies directly on clinical trial results and the management of R&D costs.

ACTU Actuate Therapeutics Inc. Company Value to Revenue (11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Actuate Therapeutics, Inc (ACTU)

- stock price and consensus target price:
- money and cash flow information:
Fundamental valuation:Actuate Therapeutics, Inc. (ACTU)
Core merchandise of Actuate Therapeutics Inc.

The EV/Sales metric determines the market value of a business, excluding the impact of debt load on the overall valuation relative to revenue. By analyzing the EV/Sales chart, an investor assesses the company's maturity level and the absence of speculative spikes. The ratio is calculated as enterprise value divided by sales, reflecting the asset's fundamental attractiveness. For Actuate Therapeutics, Inc. (ACTU), this serves as an indicator of how effectively oncology developments are capitalized. The diversification of solid tumor therapies directly influences the future dynamics of this coefficient.

Competitor analysis for Actuate Therapeutics, Inc.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio